Mr Luther Edward Beil, DO in Bath, PA - General Practice

Mr Luther Edward Beil, DO is a General Practice physician based in Bath, Pennsylvania. Mr Luther Edward Beil is licensed to practice in Pennsylvania (license number OS3290L) and his current practice location is 2667 Community Drive, Bath, Pennsylvania. He can be reached at his office (for appointments etc.) via phone at (610) 837-7423.

NPI number for Mr Luther Edward Beil is 1578721114 and his current mailing address is 2667 Community Drive, Bath, Pennsylvania. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1578721114.

Contact Information

	Mr Luther Edward Beil, DO
	2667 Community Drive, Bath, PA 18014
	(610) 837-7423
	Not Available

Physician's Profile

Full Name	Mr Luther Edward Beil
Gender	Male
Speciality	General Practice
Location	2667 Community Drive, Bath, Pennsylvania
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1578721114
Provider Enumeration Date: 05/30/2008
Last Update Date: 05/30/2008

Medical Identifiers

Medical identifiers for Mr Luther Edward Beil such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1578721114	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208D00000X	General Practice	OS3290L (Pennsylvania)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mr Luther Edward Beil is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mr Luther Edward Beil, DO 2667 Community Drive, Bath, PA 18014 Ph: (610) 837-7423	Mr Luther Edward Beil, DO 2667 Community Drive, Bath, PA 18014 Ph: (610) 837-7423

News Archive

Reducing commodity costs for ARVs could mean providing treatment to millions more people

"Reducing commodity costs for antiretroviral drugs by a mere five to 10 percent can represent hundreds of millions of dollars in savings for the global community. In turn these savings translate into millions of more patients who can receive access to life-saving treatment," David de Ferranti, president of Results for Development Institute (R4D), and Kanika Bahl, managing director at R4D, write in a Huffington Post opinion piece.

Resverlogix highlights features of RVX-208 drug at ATVB conference

Resverlogix Corp. announced today that key scientific data was communicated in an oral presentation highlighting the novel features of RVX-208, the Company's lead drug, during the Atherosclerosis, Thrombosis, Vascular Biology conference being held in San Francisco, California.

New psychiatric medication treatment guidelines for preschoolers

The number of preschool-age children being treated with stimulants, antidepressants and other psychiatric drugs is on the rise, despite limited research and a lack of clinical practice guidelines.

PSI CRO presents the changing dynamic of clinical trial feasibility at PCMG meeting

PSI CRO, a full-service contract research organization, announced today that Kasia Moscicka, Director Feasibility Research and Patient Recruitment Services, presented on the changing dynamic of clinical trial feasibility at recent PCMG meeting held in Lisbon, Portugal.

Mr Luther Edward Beil, DO - General Practice in Bath, PA